Obinutuzumab plus fludarabine/cyclophosphamide or bendamustine in the initial therapy of CLL patients: the phase 1b GALTON trial.

Blood
Jennifer R BrownThomas J Kipps

Abstract

Obinutuzumab is a type 2, glycoengineered, anti-CD20 antibody recently approved with chlorambucil for the initial therapy of chronic lymphocytic leukemia (CLL). In this nonrandomized, parallel-cohort, phase 1b, multicenter study, we explored the safety and preliminary efficacy of obinutuzumab-bendamustine (G-B) or obinutuzumab fludarabine cyclophosphamide (G-FC) for the therapy of previously untreated fit patients with CLL. Patients received up to 6 cycles of G-B (n = 20) or G-FC (n = 21). The primary end point was safety, with infusion-related reactions (88%, grade 3-4 20%) being the most common adverse event and grade 3-4 neutropenia in 55% on G-B and 48% on G-FC. Mean cycles completed were 5.7 for G-B and 5.1 for G-FC, with 2 and 7 early discontinuations, respectively. The objective response rate (ORR) for G-B was 90% (18/20) with 20% complete response (CR) and 25% CR with incomplete marrow recovery (CRi). The ORR for G-FC was 62% (13/21), with 10% CR and 14% CRi, including 4 patients not evaluable. With a median follow-up of 23.5 months in the G-B cohort and 20.7 months in the G-FC cohort, no patient has relapsed or died. We conclude that obinutuzumab with either B or FC shows manageable toxicity and has promising activity....Continue Reading

References

Mar 16, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael J KeatingHagop Kantarjian
Aug 5, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Wolfgang U KnaufMarco Montillo
Aug 17, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kirsten FischerClemens-Martin Wendtner
Aug 8, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kirsten FischerClemens-Martin Wendtner
Jan 10, 2014·The New England Journal of Medicine·Valentin GoedeMichael Hallek

❮ Previous
Next ❯

Citations

Dec 23, 2015·American Journal of Hematology·Kanti R Rai, Preetesh Jain
Mar 10, 2016·Current Hematologic Malignancy Reports·Spencer H Bachow, Nicole Lamanna
Jul 21, 2015·Cancer Treatment Reviews·Tim IllidgeGuillaume Cartron
Aug 20, 2015·Future Oncology·Jehan Dupuis
Mar 12, 2016·Expert Opinion on Drug Safety·G RedaA Cortelezzi
Mar 19, 2016·Expert Opinion on Pharmacotherapy·Candida Vitale, Jan A Burger
Apr 15, 2016·Investigational New Drugs·Yaghoub SafdariSafar Farajnia
Jun 13, 2015·Blood·Nitin Jain, Susan O'Brien
Nov 3, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R StauderV Goede
Jan 20, 2017·Nature Reviews. Disease Primers·Thomas J KippsKanti Rai
Jul 26, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jennifer R Brown, Neil E Kay
Feb 27, 2018·Current Hematologic Malignancy Reports·Craig S Boddy, Shuo Ma
Sep 13, 2017·Expert Opinion on Biological Therapy·Rabih Said, Apostolia M Tsimberidou
Dec 7, 2017·Oncoimmunology·Abhishek D GargLorenzo Galluzzi
Jan 23, 2019·Leukemia & Lymphoma·Anca Prica, Michael Crump
Dec 10, 2017·Hematology·Kirsten Fischer, Michael Hallek
Apr 2, 2019·Current Topics in Medicinal Chemistry·Benjamin Diethelm-VarelaFengtian Xue
Jun 14, 2016·British Journal of Haematology·David J M Routledge, Adrian J C Bloor
Feb 12, 2017·Current Treatment Options in Oncology·Krzysztof JamroziakJan Walewski
Aug 29, 2017·Expert Opinion on Investigational Drugs·Christian KleinGünter Fingerle-Rowson
Feb 1, 2020·Oncoimmunology·Isaure VanmeerbeekAbhishek D Garg
Mar 6, 2019·Cancers·Simon LatourLaurence Bresson-Bepoldin
Dec 3, 2016·Oncology Letters·Xiao-Lin Li, Ci-Xian Zhang
Dec 17, 2019·Therapeutic Advances in Hematology·Marisa J L AitkenSean M Post
Aug 11, 2021·Expert Opinion on Emerging Drugs·Jennifer L Crombie, Jennifer R Brown

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.